Award for Immunocore
20 Nov 2013 by Evoluted New Media
Oxford-based Immunocore has won the Best Biotech Dealmaker Award of 2013 at the OBN (Oxfordshire Bioscience Network) annual awards.
The award recognises Immunocore’s achievement in closing two major partnerships with Genentech – a member of the Roche Group – and GlaxoSmithKline to discover, develop and commercialist ImmTAC therapies against multiple targets. Each partnership involves several target programmes, each of which could result in over £200m in development and commercial milestones, plus significant royalties.
“We are delighted to win the Best Biotech Dealmaker Award against strong competition,” said James Noble, Chief Executive Officer of Immunocore. “This accolade recognises the hard work of our highly skilled team in developing our technology and in executing two significant partnership agreements, enabling up to collaborate with world-leading pharma companies to develop new treatments for cancers.”
ImmTACs exploit the power of T Cell Receptors to recognise intracellular changes occurring during viral infection or cancer. This unique ability sets them apart from traditional antibody-based therapies that only recognised changes on a cell surface, and provides the ability to develop extremely potent targeted therapies for poorly served cancers. ImmTACs can be directed to target and destroy only cancerous cells, avoiding healthy cells.
